Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Why Symantec Corporation, Biogen Idec, and Alexion Pharmaceuticals Are Today’s 3 Worst Stocks

By John Divine - Mar 21, 2014 at 7:39PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Boy, was it rough being a biotech investor on Friday: Two of today's three laggards hail from the high-flying industry.

The S&P 500 Index ( ^GSPC 0.31% ) hit all-time highs today. Then it steadily declined for the remainder of the day, driven by a slumping health-care sector. With Symantec Corporation ( NLOK -1.33% ) being the lone exception, two of the three biggest losers in the stock market today were biotechs: Biogen Idec ( BIIB 3.48% ) and Alexion Pharmaceuticals ( ALXN ) both finished near the bottom of the S&P as inquisitive congressmen spooked investors.

Shares of Symantec Corporation, which makes computer antivirus software, plunged 12.9% as the company ditched its CEO. When a company faces a dismal and uncertain future -- as Symantec has in recent years -- an easy lever to pull in an effort to jump-start growth is the makeup of the executive team. But this is an all-too-familiar process for Symantec investors, who put their faith in Steve Bennett less than 24 months ago, only to see him sent off Friday. With the company's growth uncomfortably correlated to PC sales, Symantec might be out of levers to pull.

Now for something completely different and somewhat bizzare: Shares of Biogen Idec cratered 8.2% today, even as its hemophilia B drug Aprolix was approved for sale in Canada. The sudden drop is unquestionably a direct result of unforeseen pressure from three Democratic congressmen, who sent notice to Gilead Sciences requesting an explanation of the pricing methods behind its hepatitis C drug Sovaldi. The action could be seen as an indirect threat to high-cost treatments like Aprolix, which affects just 4,000 people in the U.S and will likely cost a small fortune.

The last of the day's laggards, Alexion Pharmaceuticals, shed 8% Friday. Biogen and Alexion shares are both up more than 70% in the last year as the biotech industry's taken off with insane momentum. Expectations in the area are high, to say the least. On top of that, Alexion's only approved drug, Soliris, appears to fall under the purview of congress' crusade against high-cost treatments: the product costs $400,000 a year. That said, companies can only afford to reduce the commercial price of orphan drugs by so much, because the cost to develop the drug must be economically rewarding for public companies to produce it to begin with.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

S&P 500 Index - Price Return (USD) Stock Quote
S&P 500 Index - Price Return (USD)
^GSPC
$4,701.21 (0.31%) $14.46
Biogen Inc. Stock Quote
Biogen Inc.
BIIB
$234.72 (3.48%) $7.89
Alexion Pharmaceuticals, Inc. Stock Quote
Alexion Pharmaceuticals, Inc.
ALXN
NortonLifeLock Inc. Stock Quote
NortonLifeLock Inc.
NLOK
$24.41 (-1.33%) $0.33

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
652%
 
S&P 500 Returns
142%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/09/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.